Viz.ai: The company raised $100 million of Series D venture funding in a deal co-led by Tiger Global Management and Insight Partners on April 7, 2022, putting the company’s pre-money valuation at $1.1 billion. Scale Venture Partners, Kleiner Perkins, Threshold Ventures, GV, Sozo Ventures, CRV, and Susa Ventures also participated in the round. The company is a developer of an intelligent care coordination platform intended to fundamentally improve how healthcare is delivered in the world.
ENSEM Therapeutics: The company raised $67 million of Series A venture funding in a led by GGV Capital on April 7 2022. Mitsui Global Investment, Cenova Capital, CBC Group and Pavilion Capital also participated in the round. The company is a developer of precision drugs intended to discover, develop, and commercialize transformative oncology therapies.
Adaptive Phage Therapeutics: The company raised $61 million of Series B venture funding in a deal led by Deerfield Management on April 04, 2022. Mayo Clinic, AMR Action Fund and other undisclosed investors also participated in the round. The company is a provider of therapeutic services intended to treat multi-drug resistant pathogenic bacteria.
Enable Medicine: The company raised $60 million of Series A venture funding in a deal led by Anthos Capital and General Catalyst on April 6, 2022. Breyer Capital, Presight Capital, Axial, and Initialized Capital Management also participated in this round. The company is a developer of a bio-computational platform designed to extract valuable insights from a variety of sample types.
Avi Medical: The company raised EUR 50 million of Series B venture funding in a deal led by Balderton Capital on April 6, 2022, putting the company’s pre-money valuation at an estimated EUR 150.29 million. Daniel Dines, Heal Capital, Eurazeo, Addition, Picus Capital, Vorwerk Ventures, 3VC, Adrian Auon and Other undisclosed investors also participated in the round. The company is a provider of healthcare services intended to allow doctors and patients to work together towards better health.
Eleanor Health: The company raised $50 million in Series C funding in a deal led by General Catalyst on April 7, 2022. Warburg Pincus, Town Hall Ventures, Northpond Ventures, and Rethink Capital Partners participated in this round. The company is a provider of evidence-based outpatient care and addiction recovery services intended to help people suffering from substance abuse disorder.
Resolution Therapeutics: The company raised GBP 36.6 million of Series A venture funding from Syncona on April 5, 2022. The company is a developer of cell therapies designed to aid in the treatment of end-stage liver diseases.
Venatorx Pharmaceuticals: The company raised $34 million of Series C venture funding in a deal led by AMR Action Fund on April 4, 2022, putting the company’s pre-money valuation at $35.7 million. Abingworth Management and other undisclosed investors also participated in the round. The company is a developer of antibacterial and antiviral drugs designed to treat multi-drug-resistant (MDR) bacterial infections.
Q’Apel: The company raised $29 million of Series D venture funding from undisclosed investors on April 4, 2022, putting the company’s pre-money valuation at $91 million. The company is a developer of medical devices for the delivery of neurovascular procedures.
restor3d: The company raised $23 million of venture funding from undisclosed investors on April 5, 2022. The company is a developer of 3D printed surgical implants for multiple musculoskeletal specialties, and develops machine learning software tools for assisting engineers with patient specific implant design.
Eleos Health: The company raised $20 million of Series A venture funding in a deal led by F-Prime Capital and Eight Roads on April 5, 2022. aMoon Fund, lool Ventures and Arkin Holdings also participated in this round. The company is a developer of an artificial intelligence-backed voice technology designed to gather insights into behavioral health.
Eon: The company raised $16 million in a deal led by Integrity Growth Partners on April 6, 2022. UCHealth’s CARE Innovation Center, CU Healthcare Innovation Fund, and 25m Health also participated in the round. The company is a developer of an online clinical decision support platform designed for healthcare providers to track pulmonary nodule patients.
Endovascular Engineering: The company raised $15 million of Series A1 venture funding in a deal led by Santé Ventures and Cordis on April 05, 2022, putting the company’s pre-money valuation at $25 million. The company is a developer of vascular thrombectomy technologies designed for the management of Ischemic Stroke.
Activ Surgical: The company raised $14.6 million of Series B1 venture funding from Alumni Ventures, Tamer Hassanein, and Mo El-Bibany on April 04, 2022. Ameena El-Bibany and other undisclosed investors also participated in the round. The company provides hardware-agnostic surgical software that allows minimally invasive surgical systems (laparoscopes, arthroscopes and robots) to autonomously collaborate with surgeons.
TriFlo Cardiovascular: The company raised $13 million of venture funding from undisclosed investors on April 06, 2022. The company is an operator of a biotechnology firm focusing on an invasive transcatheter solution to treat tricuspid valve regurgitation.
Acuamark Diagnostics: The company raised venture funding from undisclosed investors on April 06, 2022. The company is a developer of a cancer screening blood technology designed to detect cancer markers at early stages.
Forge Health: The company raised $11 million of venture funding in a deal led by HC9 Ventures on April 7, 2022. The company is a provider of evidence-based outpatient care for substance use, mental health, or trauma issues.
Guard Medical: The company raised $11 million of Series B venture funding from Bpifrance and Matignon Investissement et Gestion on April 6, 2022. The company is a developer of a medical device designed to reduce surgical site infections and improve the healing process.
Lung Therapeutics: The company raised $10.1 million of venture funding from undisclosed investors on April 04, 2022. The company is a developer of novel peptide drugs intended to facilitate treatments for fibrosis and lung conditions.
Kynos Therapeutics: The company raised GBP 6.5 million of Series A venture funding in a deal led by Epidarex Capital on April 07, 2022, putting the company’s pre-money valuation at GBP 7.0 million. Scottish Enterprise and IP Group also participated in the round. The company is a developer of innovative portfolio therapies intended to revolutionize the health and well-being of patients where uncontrolled inflammation is causing suffering.
Contraline: The company raised $7.2 million of venture funding in the form of options and warrants from Amboy Street Ventures and other undisclosed investors on April 5, 2022. The company is a developer of a male contraceptive technology designed to provide non-surgical and reversible birth control procedures.
Sedimentum: The company raised CHF 3.3 million from undisclosed investors on April 07, 2022. The company is a developer of a contactless and intelligent fall and emergency detector for healthcare without compromising privacy of the patients.
